Comparative Pharmacology
Head-to-head clinical analysis: ARYMO ER versus DILAUDID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARYMO ER versus DILAUDID.
ARYMO ER vs DILAUDID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARYMO ER (morphine sulfate) is a full opioid agonist that binds to mu-opioid receptors in the central nervous system (CNS), inhibiting ascending pain pathways and altering pain perception. It also activates descending inhibitory pathways.
Dilaudid (hydromorphone) is a full opioid agonist with high affinity for mu-opioid receptors, producing analgesia by mimicking endogenous endorphins and enkephalins. It also activates kappa and delta opioid receptors to a lesser extent.
15 mg to 30 mg orally every 12 hours; titrate to effect; maximum 60 mg per dose.
Initial: 2-4 mg orally every 4-6 hours as needed; or 1-2 mg intramuscularly, subcutaneously, or intravenously every 4-6 hours as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 11–13 hours in healthy adults. This extended half-life compared to immediate-release morphine (2–4 hours) allows for once-daily dosing. In elderly or hepatic/renal impairment, half-life may be prolonged up to 22 hours.
2.5-3.5 hours (terminal); prolonged in hepatic/renal impairment
Primarily renal (90%), with approximately 10% excreted unchanged in urine; the remainder as glucuronide conjugates (morphine-3-glucuronide, morphine-6-glucuronide) and minor metabolites. Biliary/fecal excretion accounts for <10%.
Primarily renal (90% as hydromorphone-3-glucuronide and parent drug); <1% biliary/fecal
Category C
Category C
Opioid Analgesic
Opioid Analgesic